Discontinue co-trimoxazole immediately
Your patient is showing clear signs of co-trimoxazole-induced hematologic toxicity and acute kidney injury (AKI), and the drug must be stopped now. The falling blood counts (WBC, RBC, platelets) combined with rising creatinine and declining eGFR after two weeks of therapy represent well-documented adverse effects of this medication that require immediate intervention 1.
Why This Is Urgent
Co-trimoxazole causes dose-dependent bone marrow suppression and renal dysfunction through multiple mechanisms 1, 2, 3. Your patient's laboratory trends are concerning:
- Hematologic decline: WBC dropped from 8.7 to 6.7, RBC from 3.4 to 3.2, and platelets from 298 to 223—all trending downward and indicating progressive myelosuppression 4, 5, 6
- Renal dysfunction: Creatinine rose from 83 to 101 μmol/L, urea from 4.3 to 6.6 mmol/L, and eGFR fell from 75 to 59 mL/min—representing a 21% decline in kidney function 7, 2
The FDA label explicitly states that if WBC falls below 4,000/mm³ or platelets below 100,000/mm³, the drug should be stopped immediately 4. While your patient hasn't crossed these absolute thresholds yet, the downward trajectory over just two weeks is the critical warning sign 1.
Immediate Actions
Stop co-trimoxazole today—do not wait for further deterioration 4, 1
Monitor blood counts twice weekly until recovery is confirmed 4. The hematologic abnormalities typically resolve within 5-7 days after discontinuation 5, 6, 3
Check serum potassium immediately if not already done—co-trimoxazole causes hyperkalemia through trimethoprim's blockade of distal tubular Na⁺/K⁺-ATPase, particularly dangerous with declining renal function 1, 8
Ensure adequate hydration (at least 1.5 liters daily) to help clear the drug and prevent further crystalluria-related renal damage 9, 1
Recheck renal function in 48-72 hours—the creatinine elevation may be partly due to trimethoprim's inhibition of tubular creatinine secretion (without true GFR decline), but the rising urea and falling eGFR suggest genuine AKI 2, 8
Clinical Context
The renal impairment is particularly concerning because your patient's eGFR has now fallen to 59 mL/min. Guidelines recommend dose reduction when creatinine clearance drops below 30 mL/min, but AKI can occur at any level of renal function, especially with risk factors like hypertension (if present) 9, 7, 2. The study by Alappan et al. found that 11.2% of patients developed AKI with co-trimoxazole, with most cases resolving after discontinuation 2.
The bone marrow suppression is dose-dependent and cumulative 1. While frank pancytopenia (WBC <4,000, platelets <100,000) triggers mandatory discontinuation per guidelines 4, waiting for these thresholds when counts are already declining is poor practice. The American Thoracic Society guidelines emphasize that even modest declines warrant stopping the drug 4.
What NOT to Do
- Do not reduce the dose and continue—this prolongs exposure and risks progression to severe pancytopenia or renal failure 4, 1, 3
- Do not wait for "more significant" abnormalities—one case series reported a patient requiring dialysis despite prompt recognition 2
- Do not assume the creatinine rise is "just trimethoprim effect"—the elevated urea and falling eGFR indicate true kidney injury 2, 8
Recovery Expectations
After stopping co-trimoxazole:
- Blood counts typically normalize within 5-7 days 5, 6
- Renal function usually recovers within 48-96 hours if AKI is drug-induced 2, 3
- If counts don't improve within one week, consider bone marrow evaluation to exclude other causes 4, 1
Alternative Therapy
If the original infection still requires treatment, switch to an alternative antibiotic that doesn't carry these risks. The specific choice depends on the indication for co-trimoxazole (which you haven't specified), but options exist for virtually all common indications—urinary tract infections, skin infections, or Pneumocystis prophylaxis all have safer alternatives in this clinical context 9.
The key principle: co-trimoxazole toxicity is reversible if caught early but can progress to life-threatening complications if continued 1, 3. Your patient's laboratory trends over two weeks provide clear evidence that continued therapy poses unacceptable risk.